Trial investigating the safety, tolerability and efficacy of bilastine eye drops 0,6% in adults in comparison with placebo

Recruitment & Eligibility

Status: ot Recruiting

Sex: All

Target Recruitment: 300

Inclusion Criteria

1. Male or female patients aged 18 years and above.
2. Documented history of AC before V1a.
3. Documented positive skin prick test and/ or positive validated IgE test to perennial allergen (e.g. cat dander, dog dander, dust mites and/or cockroach) or to seasonal allergen (e.g. grass, ragweed, and/ or tree pollen) within 6 months before V1a or a positive skin prick test at V1a.
4. Signs and symptoms of AC, i.e. tearing, itching and redness, that are likely to continue for the next weeks. Minimum score of four on an 11-item numeric rating scale in at least one of three categories at V1a and V2a.
5. Compliant use of e-diary during the screening period (from V1a to V2a).
6. Willing to comply in all aspects of the study, including
a) use of IMP from V2a to V4a
b) attending scheduled visits and completing telephone interviews.
7. Written informed consent
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 270
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 30

Exclusion Criteria

1. History of known contraindications or sensitivities to the use of the IMP or any of its components.
2. History of intraocular surgery or planned surgery during study participation and within 2 weeks after follow-up.
3. History of ocular trauma (within the previous 6 months before V1a).
4. History or clinical evidence of ocular herpes simplex or ocular herpes zoster infectious disease.
5. History of any clinically significant external ocular disease within 30 days before V1a.
6. Presence of dry eye, active blepharitis, active meibomian gland dysfunction, active rosacea affecting the ocular surface/lid margin, active or chronic follicular conjunctivitis, preauricular adenopathy, or any other ocular or periocular abnormality that may affect study outcome.
7. Known history of recurrent corneal erosion syndrome (idiopathic or secondary to dry eye).
8. History of treatment failure to topical antihistamines.
9. Prior (within 2 years before V1a), current or anticipated anti-allergy immunotherapy.
10. Prior (within 4 weeks before V1a), current or anticipated corticosteroid treatment (systemic or local; in case of depot-corticosteroids: within 6 weeks before V1a).
11. Prior (within 1 week before V1a), current or anticipated use of any ophthalmic agents (including artificial tears), except IMP (starting at V2a).
12. Wearing of contact lenses during study participation.
13. Prior (within 2 weeks before V1a), current or anticipated systemic or intranasal treatment for allergic rhinitis.
14. Persons committed to an institution by virtue of an order issued either by the judicial or other authorities.
15. For women: Pregnancy or breast-feeding. Women of childbearing potential unable or unwilling to undergo pregnancy test(s) and practice acceptable contraceptive measures. Acceptable methods for women are surgical intervention (e.g. bilateral tubal occlusion), spermicide with barrier, oral contraceptive, injectable or implantable method of contraception, transdermal contraceptive, intrauterine device, true sexual abstinence (i.e. when this is in line with the preferred and usual lifestyle of the patient) and vasectomised male partner, provided that he is the sole partner of that patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception.
16. Patient has received an investigational drug (including investigational vaccines) or used an invasive investigational medical device within 30 days before V1a or is currently enrolled in an investigational interventional study.

Study & Design

Study Type: Interventional clinical trial of medicinal product

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method

Secondary Outcome Measures

Name	Time	Method

Related Trials